Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial-Reference-Cited by-同舟云学术

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

Published:2021-01-20 Issue:5 Volume:28 Page:1716-1725
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Ashina Messoud¹,Goadsby Peter J.²³^ORCID,Reuter Uwe⁴,Silberstein Stephen⁵,Dodick David W.⁶,Xue Fei⁷,Zhang Feng⁷,Paiva da Silva Lima Gabriel⁷,Cheng Sunfa⁷,Mikol Daniel D.⁷

Affiliation:

1. Department of Neurology Danish Headache Center Faculty of Health and Medical Sciences Rigshospitalet Glostrup University of Copenhagen Copenhagen Denmark

2. NIHR/Wellcome Trust King's Clinical Research Facility King's College London London UK

3. Department of Neurology University of California Los Angeles CA USA

4. Department of Neurology Charité–Universitätsmedizin Berlin Berlin Germany

5. Jefferson Headache Center Thomas Jefferson University Philadelphia PA USA

6. Department of Neurology Mayo Clinic Scottsdale AZ USA

7. Amgen Inc. Thousand Oaks CA USA

Funder

Amgen Foundation

Publisher

Wiley

Subject

Neurology (clinical),Neurology